You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Recent awards include:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at S&P Capital IQ Pro or S&P Capital IQ .
Bristol-Myers, Taris to evaluate Opdivo combo in bladder cancer
S&P Capital IQ Pro | Powering Your Edge
S&P Capital IQ Pro | Unrivaled Sector Coverage
Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud
Investment Research Analysts Providing Greater Coverage on Inflation
Bristol-Myers Squibb Co. and Taris BioMedical LLC will collaborate to evaluate Taris' TAR-200, in combination with Bristol-Myers' Opdivo, in patients with bladder cancer.
Under the collaboration, the combination will be evaluated in a phase 1b trial in patients with muscle invasive bladder cancer who are scheduled for radical cystectomy, or the removal of the entire bladder.
Bristol-Myers also made an equity investment in TARIS as part of the collaboration.